Tavexia Lifecare Limited has scheduled a board meeting for October 7, 2026, to deliberate on the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited. This decision follows preliminary evaluations conducted after an initial approval in September.

The meeting agenda specifically includes reviewing developments in the matter and determining the further course of action regarding the acquisition. Meyonex Pharmaceuticals is an unlisted public company. The board previously authorized designated representatives to undertake due diligence, valuation, and negotiations in relation to the deal during its meeting held on September 7, 2026.

Regulatory Compliance and Trading Window

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of Tavexia Lifecare was closed from September 30, 2026. The window will remain closed until 48 hours after the board meeting scheduled for the approval of un-audited financial results for the half year ended September 30, 2026. Designated persons and their immediate relatives are restricted from trading in the company's securities during this period.

Meeting Details

The board will also consider and transact any other business with the permission of the Chairperson. The intimation was filed with BSE Ltd under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tavexia Lifecare Limited saw a further reduction in promoter holding after Roshan Dealmark Private Limited sold 2,50,000 equity shares through an on-market transaction on September 28, 2026. This disposal follows the sale of 7,00,000 shares on September 25 and 2,00,000 shares on September 24, marking a continued marginal shift in the promoter group's stake structure.

The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company was formerly known as Sattva Sukun Lifecare Limited.

Pre and post-transaction holding

Prior to this latest sale, the combined holding of the promoter group entities, Roshan Dealmark Private Limited and Puja Agarwal, stood at 1,42,40,794 shares, constituting 3.713% of the total share capital. This figure reflects the position after the disposal of 7,00,000 shares on September 25, 2026. Following the additional disposal of 2,50,000 shares by Roshan Dealmark Private Limited, the aggregate holding decreased to 1,39,90,794 shares.

Transaction details

The shares were sold exclusively by Roshan Dealmark Private Limited, which is part of the Promoters & Promoter Group. The mode of acquisition for this specific transaction was listed as "On-market." The paid-up capital of the company remained unchanged at ₹38,36,01,248, comprising 38,36,01,248 equity shares of ₹1 each, as the sale involved existing shares rather than new issuance.

Puja Agarwal, identified as a Person Acting in Concert (PAC), retained her holding of 80,000 shares throughout the period. The disclosure confirms that there were no encumbrances, warrants, or convertible securities involved in this specific transaction event.

What the Numbers Show

The latest disposal reduced the promoter group's stake by 0.066 percentage points. Combined with the sales on September 24 and 25, the promoter group has offloaded 11,50,000 shares over three days, reducing their aggregate stake from 3.947% to 3.647%. While the absolute volume of shares sold is significant, the impact on the overall control percentage remains minimal, reflecting a slight dilution rather than a major exit strategy. The total diluted share capital remains identical to the paid-up capital, indicating no outstanding convertible instruments that would alter the voting power landscape upon full conversion.